Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent

Stock Information for ADDvantage Technologies Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ADDvantage Technologies Group Inc.

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Akari Therapeutics Releases Virtual Investor "What This Means" Segment
Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.